Adjuvant tocilizumab in the treatment of patients with moderate to severe COVID-19 pneumonia: an observational study
Journal of the Association of Physicians of India
; 70(January):14-17, 2022.
Article
in English
| GIM | ID: covidwho-1824219
ABSTRACT
Importance As there is no definitive treatment available for covid-19 pneumonia, with timed administration of tocilizumab as an adjuvant therapy in moderate to severe covid-19 pneumonia, we can reduce mortality due to cytokine storm.
1809249-37-3; adjuvants; artificial respiration; biological markers; blood pressure; blood sugar; clinical aspects; coronavirus disease 2019; cytokines; diabetes mellitus; drug therapy; efficacy; health care; hospital stay; hospitals; human diseases; inflammation; injection; intensive care units; mortality; observational studies; patients; pneumonia; remdesivir; retrospective studies; severe infections; tertiary health care; therapy; tocilizumab; viral diseases; acute infections; man; Severe acute respiratory syndrome coronavirus 2; Gujarat; India; Commonwealth of Nations; lower-middle income countries; medium Human Development Index countries; South Asia; Asia; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; biomarkers; blood glucose; glucose in blood; clinical picture; chemotherapy; death rate; SARS-CoV-2; therapeutics; viral infections
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Journal of the Association of Physicians of India
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS